Traveller’s diarrhoea

Traveler's diarrhoea is the most common illness affecting travelers. An estimated 10 million people – 20% to 50% of international travelers – develop it annually.

It is defined as three or more unformed stools in 24 hours passed by a traveler, commonly accompanied by abdominal cramps, nausea, and bloating. The primary source of infection is ingestion of fecally contaminated food or water.

Several systematic reviews have found probiotics to be effective in reducing the duration of diarrhoea in children and adults.

Amongst those Shornikova showed that after 2days of treatment with BioGaia 74 % of the patients have been free from watery diarrhoea and vomiting - published 1997 in the medical journal J. Pediatr. Gastroenterol. Nutr. Also the study from Francavilla published in 2012 showed the efficacy and safety of BioGaia Protectis while treating children with acute watery diarrhoea.

BioGaia Probiotic Drops and Tablets

Containing Lactobacillus reuteri Protectis, BioGaia Pobiotic Drops and Tablets promote the growth of good bacteria in the intestinal tract, re-establishing a healthy bacterial balance and thus significantly reduce the duration of watery diarrhoea and even increase the resistance.

BioGaia Dosage recommendations

  • for acute traveller’s diarrhoea: 1-2 times 5 drops or 1 tablet daily
  • for Rehydration: BioGaia ORS stirring 1 sachet into 250 ml safe water.
  • before the journey: 1 times 5 drops or 1 tablet daily start 2 weeks before

Prospective, randomized, placebo controlled study

Lactobacillus reuteri as a therapeutic agent in acute diarrhoea in young children.

Shornikova AV et al. J. Pediatr. Gastroenterol. Nutr. 1997;24:399-404.
Significant faster recovery from watery diarrhoea in hospitalised children supplemented with Lactobacillus reuteri Protectis.


  • The benefits of L. reuteri (BioGaia) were observed within 24 hours of onset of treatment.

  • A significant effect was apparent from the second day of treatment when 74% of patients receiving BioGaia were free from watery diarrhoea compared to 19% in the control group.

  • Vomiting practically stopped after the first day of treatment after the intake of L. reuteri (Bio- Gaia) , while it continued in the placebo group.


  • Prospective, randomized, placebo controlled study

  • 40 children aged 6-36 months hospitalised due to acute diarrhoea , 75% affected by Rotavirus

  • 1010-1011 CFU Lactobacillus reuteri (BioGaia) (n=19) or placebo (n=21) for 5 days

  • Both received standard rehydration therapy.

Double blind study

Lactobacillus reuteri DSM 17938 vs placebo in children with acute diarrhoea.

Francavilla R et al. (2012) Randomised clinical trial: Aliment Pharmacol Ther. 36: 363-369.


  • reuteri Protectis (BioGaia) significantly reduced the duration of watery diarrhoea as compared with placebo

  • Children receiving L. reuteri Protectis (BioGaia) had significantly lower relapse rate of diarrhoea.


  • Double blind, placebo-controlled study
  • 74 children aged 6-36 months hospitalised due to acute diarrhoea, 75% affected by Rotavirus
  • 4x108CFU Lactobacillus reuteri Protectis (BioGaia) (n=19) or placebo (n=21) for 5 days
  • Both received standard rehydration therapy